FSPKF (Fisher & Paykel Healthcare) Moat Score: 7/10 (As of Jun. 29, 2026)


FSPKF Fisher & Paykel Healthcare Corp Ltd FSPKF
90 GF Score
Price $22.52
GF Value $25.98
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Moat Score?

Fisher & Paykel Healthcare FSPKF +9.59% 90 Moat Score is 7 as of Jun. 29, 2026. GuruFocus rates FSPKF with a GF Score™ of 90/100 and a GF Value™ of $25.98 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 98.94% on this metric.

Fisher & Paykel Healthcare has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Fisher & Paykel Healthcare has Wide Moat: Fisher & Paykel Healthcare has a wide moat due to its strong brand, valuable patents, and significant R&D capabilities. It leads in the healthcare sector with durable cost advantages and regulatory barriers, providing sustainable market leadership and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fisher & Paykel Healthcare might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Fisher & Paykel Healthcare  (OTCPK:FSPKF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fisher & Paykel Healthcare Moat Score Related Terms

FSPKF vs ISRG, BDX, MDLN: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fisher & Paykel Healthcare Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Moat Score distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Moat Score falls into.


FSPKF
90GF Score
Fisher & Paykel Healthcare Corp Ltd FSPKF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Fisher & Paykel Healthcare (FSPKF) has a Moat Score of 7 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Fisher & Paykel Healthcare's Moat Score too high?
Fisher & Paykel Healthcare's current Moat Score is 7. Based on the distribution chart, Fisher & Paykel Healthcare ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Moat Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #9 out of 846 companies for Moat Score. This places Fisher & Paykel Healthcare in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Fisher & Paykel Healthcare's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $25.98, compared to a current price of $22.52 — trading 13.3% below its estimated fair value. The current Moat Score is 7. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current Moat Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of $22.52 is trading 13.3% below its estimated GF Value™ of $25.98. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for FSPKF:

  • Moat Score: 7
  • GF Value™: $25.98 vs. price of $22.52 (13.3% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for FSPKF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.52
Price
$25.98
GF Value